Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...